Stroke treatment academic industry roundtable: Research priorities in the assessment of neurothrombectomy devices

Stroke

Volumn 44, Issue 12, 2013, Pages 3596-3601

  Saver, Jeffrey L ^a   Jovin, Tudor G ^b   Smith, Wade S ^c   Albers, Gregory W ^d   Baron, Jean Claude ^e   Boltze, Johannes ^e   Broderick, Joseph P ^e   Davis, Lisa A ^e   Demchuk, Andrew M ^e   Desena, Salvatore ^e   Fiehler, Jens ^e   Gorelick, Philip B ^e   Hacke, Werner ^e   Holt, Bill ^e   Jahan, Reza ^e   Jing, Hui ^e   Khatri, Pooja ^e   Kidwell, Chelsea S ^e   Lees, Kennedy R ^e   Lev, Michael H ^e   Liebeskind, David S ^e   Luby, Marie ^e   Lyden, Patrick ^e   Megerian, J Thomas ^e   Mocco, J ^e   Muir, Keith W ^e   Rowley, Howard A ^e   Ruedy, Richard M ^e   Savitz, Sean I ^e   Sipelis, Vitas J ^e   Shimp, Samuel K ^e   Wechsler, Lawrence R ^e   Wintermark, Max ^e   Wu, Ona ^e   Yavagal, Dileep R ^e   Yoo, Albert J ^e   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

Endovascular recanalization; Ischemic; Reperfusion; Stroke

Indexed keywords

ARTERY OCCLUSION; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DISABILITY; EQUIPOISE; FIBRINOLYSIS; HUMAN; NEUROLOGICAL SURGICAL EQUIPMENT; NEUROTHROMBECTOMY DEVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS THROMBECTOMY; PRIORITY JOURNAL; REPERFUSION; RESEARCH PRIORITY; REVIEW; STUDY DESIGN; TISSUE INJURY;

ENDOVASCULAR RECANALIZATION; ISCHEMIC; REPERFUSION; STROKE;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; RESEARCH DESIGN; STROKE; THROMBECTOMY; THROMBOLYTIC THERAPY;

EID: 84889264114     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002769     Document Type: Review

References (38)

1. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893-903.
2. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al; SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368:904-913.
3. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914-923.
4. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al; SWIFT Trialists. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380:1241-1249.
5. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380:1231-1240.
6. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
7. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC; CLOTBUST Investigators. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J Neuroimaging. 2004;14:113-117.
8. Riedel CH, Zimmermann P, Jensen-Kondering U, Stingele R, Deuschl G, Jansen O. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011;42:1775-1777.
9. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41:2254-2258.
10. Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):333-343.
11. Saver JL. Time is brain-quantified. Stroke. 2006;37:263-266.
12. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
13. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480-2488.
14. Mazighi M, Chaudhry SA, Ribo M, Khatri P, Skoloudik D, Mokin M, et al. Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis. Circulation. 2013;127:1980-1985.
15. Shi ZS, Loh Y, Walker G, Duckwiler GR; MERCI and Multi MERCI Investigators. Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions. Stroke. 2010;41:1185-1192.
16. The Penumbra Pivotal Stroke Trial I. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40:2761-2768.
17. Kasner SE, Baren JM, Le Roux PD, Nathanson PG, Lamond K, Rosenberg SL, et al. Community views on neurologic emergency treatment trials. Ann Emerg Med. 2011;57:346-354.e6.
18. Sanossian N, Starkman S, Liebeskind DS, Ali LK, Restrepo L, Hamilton S, et al. Simultaneous ring, voice-over-internet phone system enables rapid physician elicitation of informed consent in prehospital stroke trials [abstract]. Stroke. 2008;39:708.
19. Enama ME, Hu Z, Gordon I, Costner P, Ledgerwood JE, Grady C; VRC 306 and 307 Consent Study Teams. Randomization to standard and concise informed consent forms: development of evidence-based consent practices. Contemp Clin Trials. 2012;33:895-902.
20. Menon BK, Goyal M. A systems approach towards intra-arterial management of acute ischemic stroke: need for novel outcome measures and a focus on sequence rather than steps. Interv Neuroradiol. 2011;17:296-298.
21. Almekhlafi MA, Eesa M, Menon BK, Demchuk AM, Goyal M. Ultrashort imaging to reperfusion time interval arrests core expansion in endovascular therapy for acute ischemic stroke. J Neurointerv Surg. 2013;5(suppl 1):i58-i61.
22. Abou-Chebl A, Lin R, Hussain MS, Jovin TG, Levy EI, Liebeskind DS, et al. Conscious sedation versus general anesthesia during endovascular therapy for acute anterior circulation stroke: preliminary results from a retrospective, multicenter study. Stroke. 2010;41:1175-1179.
23. Jumaa MA, Zhang F, Ruiz-Ares G, Gelzinis T, Malik AM, Aleu A, et al. Comparison of safety and clinical and radiographic outcomes in endovascular acute stroke therapy for proximal middle cerebral artery occlusion with intubation and general anesthesia versus the nonintubated state. Stroke. 2010;41:1180-1184.
24. Inoue M, Mlynash M, Straka M, Lansberg MG, Zaharchuk G, Bammer R, et al. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. Stroke. 2012;43:2494-2496.
25. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
26. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke. 2010;41:932-937.
27. Lyden PD, Meyer BC, Hemmen TM, Rapp KS. An ethical hierarchy for decision making during medical emergencies. Ann Neurol. 2010;67:434-440.
28. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
29. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al; DEFUSE 2 study investigators. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol. 2012;11:860-867.
30. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
31. Pulli B, Schaefer PW, Hakimelahi R, Chaudhry ZA, Lev MH, Hirsch JA, et al. Acute ischemic stroke: infarct core estimation on CT angiography source images depends on CT angiography protocol. Radiology. 2012;262:593-604.
32. Kamalian S, Kamalian S, Maas MB, Goldmacher GV, Payabvash S, Akbar A, et al. CT cerebral blood flow maps optimally correlate with admission diffusion-weighted imaging in acute stroke but thresholds vary by postprocessing platform. Stroke. 2011;42:1923-1928.
33. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multiarm multi-stage trials. Stat Methods Med Res. December 12, 2012. doi: 10.1177/0962280212465498.: http://smm.sagepub.com/content/early/20 12/12/12/0962280212465498. Accessed August 8, 2013.
34. Broderick JP, Tomsick TA; Interventional Management of Stroke (IMS) III Executive Committee. Reimbursement for thrombectomy devices in patients who are ineligible for intravenous tissue-type plasminogen activator. Stroke. 2013;44:1215-1216.
35. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178.
36. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30:341-354.
37. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833.
38. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145.